Abstract
Use of radiolabeled monoclonal antibodies (mAb's) that localize and bind to malignant cells continues to be an attractive mechanism for targeting and delivering either an imagable isotope, be It a y-emitter or B+-emitter, or a particle emitter such as a B—emitter or an a-emitter for therapeutic applications.
Get full access to this article
View all access options for this article.